Advancing breast cancer treatment - Workshop Report
Advancing breast cancer treatment and care in resource-limited settings
Workshop report
19 September 2024
Geneva, Switzerland
This workshop was organised as part of the World Cancer Congress 2024 by the Union for International Cancer Control, in collaboration with the WHO Global Breast Cancer Initiative, and supported by UICC’s Breast Cancer programme.
Introduction
On the occasion of the 2024 World Cancer Congress (WCC), the Union for International Cancer Control (UICC) and the World Health Organization (WHO) Global Breast Cancer Initiative (GBCI) hosted a workshop to explore ways to advance treatment and care for breast cancer in resource-limited settings. The workshop focused on how civil society and other key stakeholders in breast cancer can progress efforts towards the target for the third pillar of GBCI of at least 80% of patients completing multidisciplinary treatment, without treatment abandonment.
This workshop built upon the 2022 WCC workshop, ‘Advancing early detection of breast cancer in resource-limited settings’ held also in collaboration with WHO GBCI, which focused on the first two pillars of the initiative: health promotion for early detection, and timely diagnosis.
The workshop was interactive in format and engaged 54 participants from 33 countries including leaders from civil society organisations (CSOs), governments, academia, private sector and technical partners, enabling them to benefit from expert insights on selected topics as well as sharing their experiences.
Panel: Strategies to advance breast cancer treatment and care in resourcelimited settings
Dr Miriam Mutebi, President, AORTIC and Consultant Breast Surgical Oncologist and Assistant Professor in the Department of Surgery, Aga Khan University Hospital Nairobi
Kara Magsanoc-Alikpala, Founding President, ICANSERVE Foundation
Dr Julie Gralow, Chief Medical Officer and Executive Vice President, ASCO
Demographics of participants
Regional distribution of participants
Types of organisations represented
Group conversations
Welcome Breast cancer treatment and the WHO Global Breast Cancer Initiative
After presenting the learning objectives of the workshop, participants were invited to share the topics they would most like to explore in the workshop via an online poll, with affordability and accessibility of breast cancer treatment highlighted as the topic of most interest.
Learning objectives:
• Supporting participants in actively contributing to improving treatment and care of breast cancer in resource-limited settings;
• Increasing understanding on GBCI pillar 3 and ways to achieve its goal of at least 80% of patients completing multidisciplinary treatment;
• Highlighting challenges and opportunities to improve access to treatment for patients, including access to surgery, chemotherapy, radiotherapy, as well as supportive and palliative care in low- and middleincome countries (LMICs);
• Discussing advocacy strategies and policies that support improved access to breast cancer treatment and care;
• Emphasising the importance of patient navigation in helping to access to information and services, and hence improve their quality of life and treatment adherence.
What is the one topic you would like to explore during this workshop?
Access to radiotherapy Mulitmodal approaches
Supportive and palliative care as part of access to treatment
Strenghten surgical care for breast cancer patients
Access to breast cancer medicines in LMICs, including new ones
Affordability and accessibility of treatment
Number of responses
Dr Mary Nyangasi, Technical Officer, WHO, and Lead of the GBCI, gave the opening presentation describing the current landscape of the breast cancer burden globally, and explained the three pillars of the WHO GBCI and the principles of multimodality treatment.
In 2022, breast cancer was the most common cancer in 85% of countries and the most common or second most common cause of cancer deaths in 95% of countries globally The disease burden reflects significant disparities with a 60% survival difference between high-income and LMICs where 70% of mortalities occur. Breast cancer is often diagnosed in late stages in resourceconstrained settings when it is more difficult to treat and chances of cure are low.
Dr Nyangasi highlighted several challenges that contribute to the lack of equitable progress in achieving treatment completion without abandonment such as: the lack of access to essential medicines; the limited availability of radiotherapy; and lack of systems for patient navigation.
What is the GBCI and its third
pillar
The GBCI was designed to address the significant burden of breast cancer and aims to reduce global breast cancer mortality by 2.5% per year, with the goal of averting 2.5 million breast cancer deaths globally by 2040. Health promotion for early detection Public health education to improve awareness of the signs and symptoms, and of the importance of early detection and treatment
Dr Nyangasi explained that the foundation of breast cancer control is health promotion for early detection and prevention. Lifestyle risk factors including sedentary lifestyle, obesity and alcohol use contribute to the burden of breast cancer globally and many individuals do not have access to essential information on reducing their risk or on recognising the early signs of breast cancer. Moreover, in most countries, time to diagnosis exceeds 60 days, delaying the start of the treatment and hence resulting in poor treatment outcomes.
Principles of multimodality treatment
Dr Nyangasi highlighted the three main modalities for comprehensive breast cancer management being surgery, systemic therapy and radiotherapy. Achieving the goal of the third pillar of the GBCI, with 80% of patients undergoing multimodality treatment without abandonment, requires a multi-disciplinary approach combined with supportive management in an integrated care model. Generally, the treatment depends on the subtype of the cancer and the degree to which it has spread outside of the breast to lymph nodes (stages II or III) or to other parts of the body (stage IV). It begins with multidisciplinary planning whereby a patient-specific management plan that is evidence-based and resource-adapted is formulated.
Factors driving inequalities
Variations in treatment quality
There can be significant differences in the quality of the treatment approach used, depending on:
• Lower use of systemic therapy, surgery and radiotherapy
• Differences in types of technologies availability
• Variable use of multi-disciplinary tumour boards
Lack of access to treatment
• Delay in treatment of more than eight weeks results in survival loss of 3-5%
• Time to initiate treatment
• Treatment completion
Patient navigation and breast cancer
The pivotal role of patient navigation in all three pillars, and especially pillar 3 to help facilitate treatment was emphasised. Patient navigation is an evidence-based personalised intervention designed to guide patients through often complex cancer care systems to receive timely care, mostly in settings with limited availability, fragmented health care systems and socioeconomic barriers that hinder early detection and treatment. It has been proven to improve cancer screening rates, reduce time to diagnosis and hospital readmissions, increase adherence to surveillance appointments, improve decisionmaking and treatment knowledge, satisfaction with care and overall quality of life among cancer patients.
Dr Nyangasi explained that navigating complex health systems can cause women to abandon treatment or cause delays in treatment which result in poorer outcomes. Patient navigation is a strategy that aims to overcome individual and system-level barriers to the timely diagnosis and treatment of cancer and other chronic disease conditions. Implementing patient navigation programmes contextualised to specific settings can help achieve the GBCI overall goal of reducing breast cancer mortality rates globally.
During the workshop, the upcoming launch of the GBCI technical brief on ‘Patient navigation for early detection, diagnosis and treatment of breast cancer’ was announced, to take place on the occasion of Breast Cancer Awareness Month 2024.
The brief provides guidance to support Member States when considering the establishment of breast cancer navigation programmes. It provides an understanding of context-specific models, highlighting key considerations and specific examples of best practices for sustainable breast cancer patient navigation services, which can be subsequently adapted as a model for other major malignancies.
Finally, Dr Nyangasi stressed the importance of monitoring and evaluation, and highlighted the Cancer Surveillance Framework explaining the various surveillance measures and strategies in key populations.
Dr Nyangasi closed her presentation with several key messages highlighting that breast cancer needs to be on the global health agenda as an issue of health equity, gender equality and the right to health.
“Where you live should not determine if you live, we have all the tools we need to revolutionise access to breast cancer treatment everywhere, and save many lives.”
Dr Mary Nyangasi
Essential medicines and diagnostics lists: improving access to breast cancer treatment
Shalini Jayasekar Zürn, Senior Advocacy Manager, UICC, gave the second presentation on ensuring access to cancer medicines. She provided an overview of the WHO Model List of Essential Medicines (WHO EML) - with essential medicines being defined as those that satisfy the priority healthcare needs of a population; the WHO Model List of Essential In Vitro Diagnostics (WHO EDL) - In vitro diagnostics (IVDs) are a subset of tests or medical devices that examine specimens taken from the human body which provide essential data for screening, diagnosis and treatment; and the ATOM (Access to Oncology Medicines) Coalition - a key initiative aiming to increase access to oncology medicines.
Shalini Jayasekar Zürn also highlighted the barriers faced in accessing essential medicines (high costs of newer targeted therapies, issues with quality and supply chain) and specifically the inequalities that exist globally.
A limited range of carefully selected essential medicines leads to better health care, better medicine management, and lower costs
“Less than 50% of cancer medicines on the WHO EML are available in LMICs. The WHO EML helps countries prioritise medicines that should be made available and affordable throughout their health systems.”
Shalini Jayasekar Zürn
Additionally, access to diagnostic and pathology services are fragmented or not available and only one quarter of LMICs are reported to have pathology services. This message was echoed by participants throughout the workshop.
What is an essential medicine?
Essential medicines are those that satisfy the priority health care needs of the population
Essential medicines are selected with due regard to disease prevalence, evidence on efficacy and safety, and comparative costeffectiveness
Essential medicines are intended to be available within the context of functioning health systems at all times, in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford
The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility
Over the years, UICC has been closely involved in the review of cancer medicines on the WHO EML, including convening experts for a review of the cancer medicines in 2015. Ahead of the 2015 review, UICC and the WHO saw a need to carry out a comprehensive analysis of the cancer medicines section to inform an evidence based update. The methodology for the selection of essential cancer medicines was revised to include medicines based on specific treatment regimens for specific cancers, which would make it easier for governments to identify cancer medicines relevant for their national disease burden. Following the review, 16 new systemic therapies for cancer were added to the list bringing the total number of cancer medicines to 46 in the 2015 list compared to just 25 included in the previous list. This review was also done for the paediatric list which led to the addition of nine medicines to the WHO EML which are specifically for children. Using this methodology, the cancer section of the WHO EML is updated every two years. This list can be used for advocacy purposes in support of GBCI pillar 3.
Having well developed diagnostic systems in place is essential to achieving the second pillar of the GBCI, which is timely diagnosis, with evaluation, imaging, tissue sampling and pathology completed within 60 days and starting treatment as soon as possible. It is important that health systems also have access to essential diagnostics, as the diagnosis supports the determination of the relevant treatment for the patient. Essential diagnostics are those that satisfy the priority healthcare needs of the population and are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy and comparative cost effectiveness, similar to the definition of essential medicines. In vitro diagnostics (IVDs) are a subset of tests or medical devices that examine specimens taken from the human body that provide essential data for screening, diagnosis and treatment. Access to IVDs are crucial for the early detection of cancer.
The WHO EDL lists many IVDs for cancer including, for example HER-2 overexpression in the treatment of breast cancer. The WHO EDL aims not only to improve the health system’s capacity to reach accurate diagnoses, but to save precious health resources that would otherwise be wasted on inappropriate treatment or lengthy hospital stays. To ensure optimum use of resources, governments must select essential IVDs based on national needs and capacity for treatment and must be aligned with national essential medicines lists.
In response to the barriers of accessing essential medicines, UICC launched the Access to Oncology Medicines (ATOM) Coalition in 2022, a ground-breaking initiative bringing together over 40 global partners with the aim of increasing access to quality-assured essential cancer medicines in low- and lower middle-income countries (LLMICs) and to help countries develop the capacity for their proper use. The ATOM Coalition is committed to addressing the challenges of availability, affordability, and appropriate use of oncology medicines and diagnostics in LLMICs, with the following objectives:
• Improve the capacity to receive and use cancer medicines in targeted LLMICs.
• Secure an increasing number of patented medicines and new medicines in the pipeline.
• Make more WHO EML generic and biosimilar cancer medicines available over time.
The coalition is initially focused on cancers with the highest burden, including breast cancer.
Shalini Jayasekar Zürn concluded the presentation stressing the importance of partnerships and collaborations in securing access to essential medicines and diagnostics globally.
Panel: Strategies to advance breast cancer treatment and care in resource-limited setting
Miriam Mutebi, President of AORTIC, Consultant Breast Surgical Oncologist at Aga Khan University Hospital Nairobi, and UICC Board member started the panel conversation by sharing her perspective on challenges and opportunities in LMICs to advance breast cancer treatment.
Dr Mutebi reiterated several key messages about the current landscape of breast cancer in LMICs and inequities that exist globally in terms of access to surgery, radiation therapy, treatment, and supportive care in LMICs and highlighted that many women are diagnosed at advanced stages due to a number of personal and structural barriers such as financial constraints and sociocultural factors.
At the system level, health systems in many African countries face challenges such as inadequate infrastructure, limited availability of specialised healthcare professionals, and insufficient policy frameworks to support cancer care, which echoed the messages in the previous presentations.
At an individual level, Dr Mutebi explained that out-of-pocket expenditures often result in catastrophic health costs and financial hardship for families, and in many cases patients discontinue treatment to save money, leading to delays that reduce treatment efficacy. Additionally, sociocultural barriers, including stigma and lack of agency among women to seek healthcare independently, further impede access to timely and effective treatment.
Dr Mutebi emphasised the crucial role of surgery in cancer management, as 80% of cancer patients will require a surgical procedure. In this context, strengthening the workforce for skilled cancer surgeons is essential to enable access to timely and affordable breast cancer surgery in Africa.
“Despite efforts, progress in oncology care and increased access to radiation, cancer surgery is lagging behind in many LMICs hindering equitable access to breast cancer treatment for countless women.”
Dr Miriam Mutebi
Similarly, she stressed the importance of early detection programmes and more knowledge to be shared at the community level to try to increase the number of cases diagnosed at early stages. In summary, addressing the multifaceted challenges of breast cancer care in LMICs, particularly in Africa, requires a comprehensive approach that includes policy development, infrastructure investment, workforce training, and community engagement.
Kara Magsanoc-Alikpala, Founding President, ICANSERVE Foundation, Philippines was asked to share her experience in advocacy to develop laws supporting breast cancer patients and the value of patient navigators.
Kara Magsanoc-Alikpala discussed the challenges and strategies involved in collaborating with local governments to implement community-based cancer care programmes. She explained that establishing partnerships often requires identifying a ‘champion’ to serve as a bridge to key political figures, such as the mayor. While mayors are usually open to discussions, health programme implementers, such as city health offices, often express scepticism, fearing increased workloads, political misuse of programmes, or additional responsibilities without compensation. To ensure sustainability, she emphasised the importance of embedding programmes into local laws, making them harder to repeal and ensuring their continued implementation and funding.
A key focus of strong health programmes, as outlined by Kara Magsanoc-Alikpala, is patient navigation, which aims to promote early cancer detection, reduce mortality, and improve patients’ quality of life with minimal out-of-pocket expenses. Kara MagsanocAlikpala shared her experience in Taguig City, in the Philippines, where a patient navigation law was developed and has proved to have positive outcomes.
The programme is unique in the Philippines, particularly in its community-based approach. Taguig City emerged as a model of success, with patient navigators who receive salaries, benefits and security of tenure being assigned to specific villages to ensure personalised and consistent support. The initiative has also involved intensive community engagement to gain trust and participation. For example, public events feature patient testimonials, health screenings, and interactive setups in community spaces to educate and encourage participation. This creative approach helps dispel myths about breast cancer, framing it as neither a death sentence nor contagious, while promoting available resources.
Community health workers (CHWs) play a pivotal role in the programme. Often women with limited formal education and minimal pay, these workers have proven indispensable in conducting screenings, supporting patients, and tracking progress. Despite their contributions, many face financial and job security challenges, prompting ongoing advocacy for better compensation and career development opportunities. Kara MagsanocAlikpala underscored the importance of empowering these workers to sustain the programme’s success.
“Having patient navigation as a career path is something we should advocate for. Our health system is driven by community health workers, however, in some settings, navigators are volunteers and not compensated for their work, despite their importance in ensuring patients complete treatment”
Kara Magsanoc-Alikpala
The programme also introduced a digital innovation called the ‘Circle of Life’, a platform designed to monitor and analyse gaps in cancer care. This tool enables local governments to make data-driven decisions. While initial concerns arose about navigators’ ability to use the platform due to their limited educational backgrounds, they quickly adapted and outperformed even the doctors in data input and management. The platform has already identified critical issues, such as broken mammogram machines, leading to actionable solutions like equipment repair and replacement. It also helps track compliance with the KPIs of the GBCI outlined by the WHO.
The impact of these efforts is evident. In Taguig City, the time from the detection of an abnormality to diagnosis was reduced from six months to 45 days, and 90% of patients now complete their treatment, up from 88% the previous year. Despite these successes, significant challenges remain, including the absence of a national community-based cancer control programme in the Philippines despite the passage of the National Integrated Cancer Control Act of 2019.
Kara Magsanoc-Alikpala expressed hope that their model would inspire broader adoption and continued improvements. She also acknowledged that the programme’s codesign with patients and its culturally sensitive approach have been key to its sustainability and effectiveness.
Julie Gralow, Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology (ASCO), USA was asked to discuss the role of clinical breast cancer guidelines in supporting improved access to breast cancer care and how advocates can influence policy to improve access to breast cancer treatment.
Dr Gralow provided a comprehensive overview of the evolution and impact of breast cancer care guidelines, tracing their development from the 1990s, including her role in co-chairing the development of ASCO’s resource-stratified, now global, guidelines. She emphasised that guidelines play a crucial role in standardising care by defining consistent, evidence-based protocols that discourage outdated practices and optimise patient treatment. Updated regularly, these guidelines ensure high-quality care regardless of location or provider, and aid policymakers and health systems in efficiently allocating resources by identifying costeffective ‘best buys’.
Guidelines also serve as educational tools, raising awareness and reducing disparities by addressing socioeconomic and geographic barriers. By providing clear protocols, they minimise variability in care delivery and eliminate unnecessary tests, promoting costeffective and equitable healthcare. Dr Gralow noted that guidelines are essential for quality improvement.
Panel: Strategies to advance breast cancer treatment and care in resource-limited setting
Panel: Strategies to advance breast cancer treatment and care in resource-limited setting
They allow health systems to assess their performance, identify gaps, and implement changes to meet benchmarks. For rural or under-resourced areas, guidelines can set standards for when to refer patients to specialised centres, ensuring everyone receives the best possible care.
For instance, introducing population-based mammography screening should only occur when diagnostic mammography and biopsy services are in place to address symptomatic cases.
Group conversations
“Guidelines can be used for awareness and education and they can help reduce disparities by contributing to reduce the provider variability, address socioeconomic and geographical barriers, and help with cost effectiveness in general.”
Dr Julie Gralow
Transitioning to advocacy, Dr Gralow highlighted how guidelines empower patient advocates. They provide advocates with evidence-based tools to engage policymakers effectively, avoiding conflicting demands that can derail progress. She stressed the importance of resource stratification, urging advocacy groups to align their goals with the available infrastructure and capacity.
Dr Gralow shared an impactful example from Uganda, where a small grants programme enabled breast cancer advocacy groups to influence policy. The Uganda Women’s Cancer Support Organisation used their grant to host a lunch with female parliamentarians, raising awareness about breast and cervical cancer. This strategic initiative gained significant traction, leading to national-level discussions and subsequent funding opportunities for the group. Dr Gralow highlighted how this project demonstrated the power of small, but welltargeted initiatives to inspire confidence, build capacity, and achieve lasting impact. She concluded by encouraging advocates to collaborate, avoid conflicting requests to policymakers, and leverage guidelines and small successes to drive systemic change. Her experiences underscored the importance of collective effort, strategic advocacy, and the role of well-crafted guidelines in improving access to breast cancer care globally.
Participants were assigned to groups based on their topics of interest, indicated at the beginning of the workshop. Groups discussed barriers and enablers from the lens of the assigned topic and finally discussed what would be needed to achieve the third pillar of the GBCI.
National implementation
The group highlighted main barriers to implementing and achieving the target for the third pillar of GBCI nationally, including financial constraints, healthcare workforce shortages, inadequate infrastructure, and fragmented health systems. Cultural factors, poor-quality diagnostics, corruption, and insufficient palliative care were perceived to further hinder progress, alongside high outof-pocket costs for patients. Key enablers for improvement highlighted included national guidelines, universal health coverage (UHC), comprehensive care centres, and strong governance. Advocacy, public-private partnerships, healthcare worker training, datadriven policies, telehealth, and navigation programmes were also identified as crucial for better outcomes.
→ Moving forward, the group perceived strong legal frameworks and corruptionfree governance as essential. Investment in infrastructure, workforce training, and multidisciplinary teams (MDTs) will support effective implementation. Patient-centred navigation systems and social support structures were considered to be vital to ensure continuity of care.
Advocacy and patient voices
Main barriers identified to achieve GBCI target 3 identified by this group include financial challenges, limited availability and high costs of new drugs, and gaps in patient education, particularly regarding treatment completion. Inadequate infrastructure further restricts outreach and awareness efforts from advocates.
Enablers proposed include developing alternative financing models, decentralisation of treatment modalities, and acceleration of drug registration processes. Universal health coverage was also emphasised as an enabler to improve access to treatment.
→ Moving forward, the group identified advocacy for infrastructure development and patient education as critical in raising patient voices. Increasing drug accessibility through public-private partnerships and alternative financing schemes is also a priority.
Multimodal treatment, including palliative and supportive care
Barriers highlighted by this group include limited access to supportive and palliative care, inadequate training, and poor integration of traditional healers and community health workers into care pathways.
Enablers suggested include digital health tools, workforce training, and involvement of primary care providers in holistic care models. Community and faith-based support systems were also noted as crucial.
→ The group recommended a patientcentred approach, combining MDTs, virtual education, and advocacy. Building trust and acceptance within communities, while monitoring and evaluating progress, is key.
Access to essential medicines
Main barriers identified to achieve GBCI target 3 identified by this group include financial challenges, limited availability and high costs of new drugs, and gaps in patient education, particularly regarding treatment completion. Inadequate infrastructure further restricts outreach and awareness efforts from advocates.
Enablers proposed include developing alternative financing models, decentralisation of treatment modalities, and acceleration of drug registration processes. UHC was also emphasised as an enabler to improve access to treatment.
→ Moving forward, the group identified advocacy for infrastructure development and patient education as critical in raising patient voices. Increasing drug accessibility through public-private partnerships and alternative financing schemes is also a priority.
Several themes were reoccurring in the various groups as enablers to achieving the third target of the GBCI:
• Policy/UHC/national budget
• Navigation programmes
• Training programmes for healthcare workers
• Quality indicators
• Public-private and other partnerships
• Patient education and navigation and shared decision-making
The workshop closed with a Q&A session and an online poll to assess learning and key takeaways for participants. The Q&A session generated rich discussion that demonstrated the learning that had taken place during the workshop, and added further nuance and clarity regarding specific contexts or aspects of early detection. Participants took an online poll to share which their main learnings, with the majority of those relating to having a better understanding of the EML and EDL, the importance of companion diagnostics for access to medicines, as well as patient navigation and multimodal treatment.
The workshop closed by encouraging participants to engage virtually on the UICC Connect platform, and continue to connect on the topic, in particular highlighting the opportunity of the UICC Global Breast Cancer Initiative foundational online course.
Adamu Alhassan Umar, President/CEO, Nigerian Cancer Society, Nigeria
Alexandra Núñez, President, Unidos Contra el Cáncer, Costa Rica
Ana Paula Correa Refinetti, Associate Professor, Department of Breast Surgical Oncology, MD Anderson, USA
Anna Cabanes, Senior Advisor, Global Focus on Cancer, USA
Lacy Hubbard, President, Elekta Foundation, Sweden
Lilian Genga, Nurse - Program Officer, Ministry of Health National Cancer Control Program, Kenya
Lily Gutnik, Assistant Professor, University of Alabama at Birmingham, USA
Lisseth Ruiz de Campos, President, Asociación Salvadoreña para la Prevención del Cáncer, El Salvador
Lucilla Pang, Sabah Delegate, National Cancer Society Malaysia, Malaysia
Maira Caleffi, Founder / President, Federação Brasileira de Instituições Filantrópicas de Apoio à Saúde da Mama, Brasil
María Lasierra Losada, Technical Officer, WHO, Denmark
Mariam Ibrahim, Assistant Manager Media & Communication, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan
Mary Hemrajani, Chairman, Global Chinese Breast Cancer Organizations Alliance, Hong Kong SAR China
Mary Nyangasi, Technical Officer, WHO, Switzerland
Mélanie Samson, Senior Technical Officer, Women’s Health, Global Surgery Foundation, Switzerland
Miriam Mutebi, President, AORTIC and Consultant Breast Surgical Oncologist and Assistant Professor in the Department of Surgery, Aga Khan University Hospital, Nairobi, Kenya
Muriel Auclaire, Head of Membership, UICC, Switzerland
Nayi Zongo, Surgical Oncology Professor, Coalition Burkinabè Contre le Cancer (COBUCAN), Burkina Faso
Nur Aishah Mohd Taib, Professor, Universiti Malaya, Malaysia
Ophira Ginsburg, Senior Scientific Advisor for Clinical Research, National Cancer Institute, USA
Pamela Were, Community Outreach Chief Coordinator, International Cancer Institute, Kenya
Pat Gonzales, Chief Executive Officer, The Max Foundation, USA
Rizu Rizu, Project Manager, Global Breast Cancer Initiative, WHO, India
Simon Boni, Head of Multisector Partnerships, National Cancer Control Programme, Côte d’Ivoire
Sithabiso Masuku, Research Associate, University of Sheffield, United Kingdom
Somesh Kumar, Senior Director, Technical Leadership and Innovation, and Country Director India, Jhpiego, India
Sonia Ujupan, Executive Director, Oncology Corporate Affairs, International, Eli Lilly and Company, Belgium
Tarishi Desai, Manager - Treatment & Supportive Care, McCabe Centre for Law & Cancer, Australia
Tiara Bunga Mayang Permata, Radiation Oncologist, Cipto Mangunkusumo National General Hospital Indonesia, Indonesia
Tricia Fitzsimmons, Executive Director & Head, Global Policy - Oncology, Novartis, USA
Tsetsegsaikhan Batmunkh, Chief Executive Officer, National Cancer Council of Mongolia, Mongolia
Udie Soko, Executive Director, Zambian Cancer Society, Zambia
Venus Mushininga, Program Manager, Department of NonCommunicable Diseases, Ministry of Health and Child Care, Zimbabwe
Yuval Cohen, Project Coordinator, United Nations Institute for Training and Research, Switzerland
Partners and collaborators
This workshop was delivered as part of UICC’s Breast Cancer Programme, kindly supported by the following UICC partners. UICC’s Breast Cancer Programme aims to contribute to the reduction of premature deaths from breast cancer and improve the quality of life of patients, by strengthening the capacity of key breast cancer actors and engaging them in support of the WHO GBCI targets.
Partners supporting this workshop: In collaboration with:
